Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SANA with free AI briefings, catalyst countdowns, and dilution alerts.

SANA · Sana Biotechnology, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 10.2 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), a shelf registration filed Mar 3, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$121.7M Cash on Hand
10.2mo Cash Runway
Follow SANA by email Get an email when SANA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SANA, unsubscribe in one click. Privacy

📣 What SANA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Allogeneic Hypoimmune Anti-CD22 CAR T-cells… Non Hodgkin's Lymphoma Phase 1 · NCT06285422 Active not recruiting
Persicabtagene Lemgedleucel (SC291) Non Hodgkin Lymphoma Phase 1 · NCT05878184 Active not recruiting
UP421 Type1diabetes Early Phase 1 · NCT06239636 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SANA holds $121.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $35.8M/quarter from operations, an estimated runway of 10.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 77 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SANA files for a raise →

👥 Who Owns SANA

Insiders 5.1% Other 5%+ holders 15.4% Institutions (269 holders) 77.5% Public and other holders 2%
HolderTypeShares% of sharesAs of
Robert Nelsen 5%+ holder (13G) 46,173,125 15.41% 2026-06-30
FMR LLC Institution (13G, 5%+) 37,293,854 12.45% 2026-09-30
RA Capital Management, L.P. Institution (13G, 5%+) 18,750,000 6.26% 2026-05-14
BlackRock, Inc. Institution (13G, 5%+) 13,643,304 4.55% 2025-12-31
Steve Harr
President & CEO, Director · +1.75M options
Insider 8,960,751 2.99% 2026-03-06
Hans Edgar Bishop
Director · +170,000 options
Insider 5,863,480 1.96% 2026-10-05
Susan D. Wyrick
SVP, Finance and Accounting and Principa · +405,350 options
Insider 196,196 0.07% 2026-03-06
Dhavalkumar Dhirajlal Patel
EVP, Chief Scientific Officer · +250,000 options
Insider 183,352 0.06% 2026-08-26
Bernard J Cassidy
EVP & General Counsel · +273,126 options
Insider 112,990 0.04% 2025-03-06

Share count 299,634,951 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SANA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SANA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.